Intelligent Bio Solutions Inc. (INBS) Financial Statements (2025 and earlier)

Company Profile

Business Address 135 W 41ST ST,
NEW YORK, NY 10036
State of Incorp. DE
Fiscal Year End June 30
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2024
MRQ
6/30/2024
6/30/2023
6/30/2022
6/30/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6,3041,5378,23812,574
Cash and cash equivalent6,3041,5378,23812,574
Receivables4302941,5302,099
Inventory, net of allowances, customer advances and progress billings778980  
Inventory778980  
Other current assets4985537472,509
Other undisclosed current assets5254993531,025
Total current assets:8,5343,86310,86818,207
Noncurrent Assets
Operating lease, right-of-use asset307546  
Nontrade receivables   1,0933,148
Property, plant and equipment566690391 
Intangible assets, net (including goodwill)4,3725,255  
Intangible assets, net (excluding goodwill)4,3725,255  
Other noncurrent assets    504
Total noncurrent assets:5,2456,4921,4843,652
TOTAL ASSETS:13,77910,35512,35221,859
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,7052,6101,6251,570
Accounts payable 6021,196  
Accrued liabilities607777  
Other undisclosed accounts payable and accrued liabilities4956371,6251,570
Deferred revenue2,4872,3382,8372,099
Debt515353  
Due to related parties  13
Other undisclosed current liabilities744582201 
Total current liabilities:5,4515,8844,6633,683
Noncurrent Liabilities
Long-term debt and lease obligation  403  
Long-term debt, excluding current maturities  403  
Liabilities, other than long-term debt813561,0933,148
Deferred revenue   1,0933,148
Operating lease, liability81356  
Other undisclosed noncurrent liabilities64255122
Total noncurrent liabilities:1457841,1433,170
Total liabilities:5,5966,6685,8066,853
Equity
Equity, attributable to parent8,3293,7996,62515,058
Preferred stock    13
Common stock3523149136
Treasury stock, value(0)(0)  
Additional paid in capital60,97246,15938,44038,440
Accumulated other comprehensive loss(713)(575)(788)(661)
Accumulated deficit(51,964)(41,808)(31,176)(22,870)
Equity, attributable to noncontrolling interest(146)(112)(79)(51)
Total equity:8,1833,6876,54615,007
TOTAL LIABILITIES AND EQUITY:13,77910,35512,35221,859

Income Statement (P&L) ($ in thousands)

12/31/2024
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Revenues3,1121,2574371,980
Cost of revenue(1,686)(930)  
Cost of product and service sold(70)(190)  
Other undisclosed gross profit    
Gross profit:1,4263274371,980
Operating expenses(12,134)(13,660)(8,774)(7,554)
Government assistance, operating income, increase (decrease)
Other undisclosed operating income425738  
Operating loss:(10,283)(12,595)(8,337)(5,573)
Nonoperating income (expense)921,9313(1,487)
Investment income, nonoperating   (136)
Loss, foreign currency transaction, before tax(1)(10)(4) 
Interest and debt expense(167)(224)(8)(1,094)
Loss from continuing operations before equity method investments, income taxes:(10,358)(10,888)(8,342)(8,154)
Other undisclosed income from continuing operations before income taxes    1,094
Loss from continuing operations:(10,358)(10,888)(8,342)(7,060)
Loss before gain (loss) on sale of properties:(8,342)(7,060)
Other undisclosed net income1672248 
Net loss:(10,191)(10,665)(8,334)(7,060)
Net income attributable to noncontrolling interest34332823
Net loss available to common stockholders, diluted:(10,157)(10,632)(8,306)(7,037)

Comprehensive Income ($ in thousands)

12/31/2024
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Net loss:(10,191)(10,665)(8,334)(7,060)
Other undisclosed comprehensive income (loss)(137)213(127)(297)
Comprehensive loss:(10,328)(10,452)(8,461)(7,358)
Comprehensive income, net of tax, attributable to noncontrolling interest34332823
Comprehensive loss, net of tax, attributable to parent:(10,294)(10,419)(8,433)(7,335)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: